Flotations tank in the first quarter
A correction – as long as it is not too severe – might not be a bad thing for the sector.
Crunch time for the Spac space
This month has seen two blank-cheque company deals fall apart, and more terminations should be expected.
Medical device groups float – then sink
Medtechs rushed for the markets last year, but had an uneasy time once there.
Free to download now: Evaluate Vantage’s 2022 Preview
Explore what might be in store for biopharma next year in our new report, with new data analyses, catalyst tables and investor interviews.
Biotech listings show signs of a slowdown
2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.
The heat is on for Oxford Nanopore
Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.
